QUVROTTA Trademark

Trademark Overview


On Wednesday, November 18, 2020, a trademark application was filed for QUVROTTA with the United States Patent and Trademark Office. The USPTO has given the QUVROTTA trademark a serial number of 90327753. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 9, 2024. This trademark is owned by Eli Lilly and Company. The QUVROTTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
quvrotta

General Information


Serial Number90327753
Word MarkQUVROTTA
Filing DateWednesday, November 18, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 8, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 22, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Saturday, November 21, 2020NEW APPLICATION ENTERED
Friday, January 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 8, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 8, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, April 29, 2021ASSIGNED TO EXAMINER
Monday, May 3, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 19, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 3, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 11, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022SOU EXTENSION 2 GRANTED
Tuesday, January 11, 2022SOU EXTENSION 1 FILED
Thursday, January 20, 2022SOU EXTENSION 1 GRANTED
Thursday, January 20, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, January 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 13, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022SOU EXTENSION 2 FILED
Thursday, January 12, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 12, 2023SOU EXTENSION 3 FILED
Thursday, January 12, 2023SOU EXTENSION 3 GRANTED
Saturday, January 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 11, 2023SOU EXTENSION 4 FILED
Tuesday, July 11, 2023SOU EXTENSION 4 GRANTED
Thursday, July 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 10, 2024SOU EXTENSION 5 FILED
Tuesday, January 16, 2024SOU EXTENSION 5 GRANTED
Wednesday, January 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 9, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 9, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED